Innoventric successfully completed a $28.5 million funding round led by RA Capital, aimed at supporting clinical trials for its innovative system developed for tricuspid heart valve replacement.
The system assists in treating severe blood leakage issues, and the investment will be used to expand the company’s clinical trials in the United States and Europe. Our firm has been advising Innoventric since its establishment, and we congratulate them on another impressive milestone in their dedication to finding a solution for such an important issue.
This successful round was led by partner Peter Sugarman, adv. Vered Glaubach and interns Sammy Liebert and Tama Sicron.
